Untreated chronic hepatitis C or B infection in HIVinfected patients has been associated with an increased frequency of AIDS-related [1] and non-AIDS-related clinical end points, such as end-stage liver diseases, including cirrhosis and hepatocellular carcinoma [2] . The outlook of chronic hepatitis B treatment in the context of HIV infection has greatly improved since the introduction of tenofovir disoproxil fumarate (TDF), a reverse transcriptase nucleotide analogue first used in 2001 for controlling HIV infection [3] . Viral kinetics of HBV under TDF has now been extensively studied, both in patients with lamivudine-resistant strains [4] [5] [6] , and recently in treatment-naive patients with or without concomitant lamivudine or emtricitabine [7] . Two recent clinical trials conducted in HIV-HBV-coinfected patients have confirmed the non-inferiority of TDF antiviral activity regarding HBV compared with adefovir [8] and lamivudine [9] making this molecule a
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Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use Introduction preferred choice for first-line treatment in HIV-HBVcoinfected patients [10] .
As noted among HBV-monoinfected patients participating in the REVEAL study, the prognosis of liver disease is directly linked to the level and duration of HBV replication [11, 12] . A sustainable, suppressive effect on HBV replication is therefore essential in order to mitigate the progression of prognostic indicators of liver disease, such as liver inflammation and fibrosis. Data on the use of TDF and its effect on liver fibrosis are scarce and thus far pertain only to HBV-monoinfected patients, as reported in a clinical trial comparing TDF versus adefovir dipivoxil that led to the licensing of TDF for use in HBV monoinfection [13] .
We observed patients who had long-term treatment with TDF in the French HIV-HBV Cohort Study with the aim of analysing the biochemical and histological effect of TDF on liver fibrosis in HIV-HBV-coinfected patients and determining the risk factors for its progression or regression.
Methods

Study population
Patients were selected from the French HIV-HBV Cohort Study as described previously [14] . Briefly, this 3-year prospective study recruited 308 patients in seven centres located in Paris and Lyon, France, from May 2002 to May 2003. All patients provided written informed consent to participate in the cohort and the protocol was approved by the Pitié-Salpêtrière Hospital Ethics Committee (Paris, France) in accordance with the Declaration of Helsinki.
A subgroup of 148 patients initiating TDF therapy was analysed. Patients were included in the present study based on the following criteria: HIV-positive serology confirmed by western blot, hepatitis B surface antigen (HBsAg)-positive serology for ≥6 months, available blood sample at TDF initiation and at least one other available blood sample ≥12 months after TDF initiation. Patients with previous or concomitant therapy with lamivudine, adefovir dipivoxil and/or interferonbased treatment were also included.
Basic demographic characteristics, such as age, country of origin and mode of transmission were collected at inclusion of the cohort study. Durations of HIV and HBV infections were estimated from the first positive HIV serology and first serum HBsAg positivity. Liver enzymes and biochemical parameters were obtained at inclusion of the cohort and during follow-up, and quantified using standardized methods. Liver-related pathologies (that is, compensated and decompensated cirrhosis, portal hypertension and hepatocellular carcinoma) were reported at inclusion and during follow-up. HCV and HDV seropositivity were determined using commercial ELISA assays testing for the presence of anti-HCV and anti-HDV antibodies. HBV viral loads were quantified with commercial PCR-based assays (COBAS ® AmpliPrep/COBAS ® TaqMan ® HBV Test with a detection limit of 12 IU/ ml and COBAS ® Amplicor HBV Monitor Test with a detection limit of 60 IU/ml; Roche Diagnostics, Meylan, France) and HIV viral loads were measured using either a branched-DNA (b-DNA Quantiplex 3.0 with a detection limit of 50 copies/ml; Bayer Diagnostics, Cergy Pontoise, France) or real-time PCR technique (COBAS ® AmpliPrep/COBAS ® TaqMan ® HIV-1 Test with a detection limit of 40 copies/ml; Roche Diagnostics).
The closest cohort study visit (±6 months) to TDF initiation was selected as baseline and the closest annual cohort visits were used to define 12, 24 and 36 months after treatment initiation.
Evaluation of liver fibrosis
First, we assessed liver fibrosis using the Fibrometer, a non-invasive biochemical score that has been demonstrated to accurately reflect the level of liver fibrosis in HCV and HBV monoinfection and HIV coinfection [15] [16] [17] . Fibrometer was calculated at TDF initiation and every 12-month visit thereafter using six biochemical markers (α2-macroglobulin, hyaluronic acid, aspartate aminotransferase [AST], platelets, prothrombin and urea), as well as gender and age. A total of 475 Fibrometer calculations were performed using the modified formula published in 2009 [18] . If a data point necessary for score computation was missing, values were imputed using the other biochemical markers in the Fibrometer equation. Overall, 121 (25.5%) of the Fibrometer scores used imputed values, of which 86.7% required only one imputation. Metavir [19] F2, F3, and F4 equivalents were defined using cutoff values previously validated in HIV-HBV-coinfected patients [17] , that is, F2=0.46, F3=0.69 and F4=0.83. For initial analyses, patients were stratified by baseline Fibrometer scores for the following Metavir equivalents: F0-F1, F2 and F3-F4. Because of biochemical similarities in the F0-F1 and F2 baseline Fibrometer groups, these groups were combined for the generalized estimating equation (GEE) models.
Second, a subset of 38 patients had two biopsies in which the first was performed <12 months before treatment initiation and a second during the course of TDF treatment. Paraffin-embedded biopsies were stained with haematoxylin-phloxin-saffron and picrosirius red, then scanned using an automated virtual slide scanning robot with a 20× microscope objective and 0.23 µm/pixel resolution (Mirax Scan; Zeiss, Göttin-gen, Germany). Initial reading was performed by three pathologists who were unaware of the clinical and biological data, except for the diagnosis of chronic HBV infection and HIV infection. A consensual result was elaborated by re-evaluation of any case with a different final assessment exceeding one point for activity or fibrosis. Intraobserver concordance and performance of virtual slide reading have been previously assessed and are considered very satisfactory [20] . Fibrosis staging was done according to Metavir classification [19] (A0 no activity, A1 mild activity, A2 moderate activity, A3 severe activity, F0 no portal fibrosis, F1 portal fibrosis without septa, F2 portal fibrosis with few septa, F3 portal fibrosis with many septa but no cirrhosis and F4 cirrhosis). Because liver biopsies were performed by physician discretion and were not randomly selected, differences in demographic and HIV or HBV infection characteristics were examined between patients with and without biopsies to determine any bias. The total number of patients with stable or transitioning levels of Metavir fibrosis (grouped as F0-F1 versus F2 versus F3-F4) and activity (grouped as A0-A1 versus A2-A3) was quantified.
Statistical analyses
Demographic and biochemical characteristics, including HIV and HBV virological data, were summarized using means (±sd), medians (interquartile range [IQR]) or proportions for each group of baseline Fibrometer score. Group-by-group comparisons were made using a Pearson's χ 2 test or Fisher's exact test for categorical and a Kruskal-Wallis test for continuous variables. Median (25-75th percentiles) levels of liver enzymes were calculated at every follow-up visit and each 12-month visit was compared to baseline using a Kruskal-Wallis equality-ofpopulations rank test. The incidence of liver-related diseases was estimated by person-years of TDF exposure.
The mean change from baseline (∆) in Fibrometer score was calculated for each annual follow-up point and then modelled using a GEE with an exchangeable working correlation. This model accounts for interpatient correlation in ∆ measurements and was adjusted for the following confounding variables known to affect the level of liver fibrosis: serum HBV viral load (per log 10 IU/ ml), concomitant treatment with lamivudine, median age (>40.6 years), indicated CD4 + T-cell count for treatment initiation (>350 cells/mm 3 ), median body mass index (BMI; >22.3 kg/m²) alcohol consumption (>4 glasses/ day) and positive HCV and/or HDV serology. Improvement in liver fibrosis was defined as at least a one-stage decrease in biochemical score at the end of follow-up, similar to other studies in HBV-infected patients (treated with lamivudine) [21] and HCVinfected patients (treated with pegylated interferon and ribavirin) [22] . Homogeneous continuous-time Markov models with both time-independent and timedependent covariates were used to study risk factors for regression or progression of liver fibrosis between scores. Time-dependent variables were assumed to be constant between observations. Transition rates during follow-up were modelled between F0-F2 and F3-F4 fibrosis scores. Univariate hazard ratios (HRs) were estimated using maximum likelihood methods. A Wald test was used to determine the predictive significance of variables. To test the goodness-of-fit, the predicted patient transitions were computed with the fitted models and compared to observed values with a MantelHaenszel χ 2 test [23] .
Results
Study population characteristics
The 148 patients included in this study are described in Before inclusion, 108 (73.0%) and 10 (6.8%) patients had been exposed to lamivudine and/or adefovir dipivoxil, respectively, with no significant differences between baseline Fibrometer groups. Pegylated interferon was administered prior to inclusion in only 6 (4.1%) patients with baseline F3-F4. Antiretroviral treatment at TDF initiation was as follows: 1 nucleoside/nucleotide reverse transcriptase inhibitor (NRTIs) plus 1 protease inhibitor (PI; n=53); 1 NRTI plus 1 non-NRTI (NNRTI; n=47), 2 NRTIs (n=28), 1 NNRTI plus 1 PI (n=17), 2 PIs (n=2) and 1 NRTI (n=1).
Of the 148 patients included, 5 stopped TDF after a mean ±sd duration of 20.4 ±8.5 months. Reasons for TDF interruption included end-stage liver disease (n=1), suspected treatment-induced nephrotoxicity (n=1), HIV virological failure (n=1), therapeutic simplification to lamivudine/abacavir/zidovudine (n=1) and poor adherence (n=1).
Liver-related morbidity during TDF treatment
The median follow-up for patients under TDF treatment was 29.5 months (IQR 17.1). No patient had end-stage liver disease (that is, decompensated cirrhosis or hepatocellular carcinoma) at inclusion. In total, 33 (22.3%) cases of F4 score were documented by Fibrometer before TDF introduction. In the remaining 115 patients, 12 had an incident F4 score at an overall rate of 4.5 per 100 person-years (cumulative incidence 10.4%), occurring after a median 11.2 months (IQR 8.4) of treatment. A total of 2 patients out of 12 (16.7%) had a concurrent HDV or HCV infection.
No deaths were noted in the study population. Two patients presented with liver failure during treatment (incidence rate 0.6/100 person-years). One patient with a Metavir fibrosis score of F2 at baseline was on TDF for 30 months until treatment was discontinued because of liver failure. This patient had an undetectable HBV DNA viral load (<38 IU/ml), however was coinfected with actively replicating HDV (HDV viral load prior to treatment discontinuation was 33,000 copies/ml) with peak liver enzyme activities at 94 IU/ml for alanine aminotransferase (ALT), 130 IU/ ml for AST, 229 IU/ml for γ-glutamyl transpeptidase (GGT), and a concentration at 58 IU/ml for total bilirubin. The second patient had a baseline Metavir fibrosis score of F4 and had positive HCV and HDV serology. Liver failure occurred 22 months after TDF initiation. The patient continued treatment and, after 36 months, a biopsy demonstrated a Metavir fibrosis score of F4. Although ALT and AST were low (42 and 46 IU/ml, respectively) and HBV DNA viral load was undetectable at the end of follow-up, hyaluronic acid concentration was high (419 µg/l). at TDF initiation; P=0.009), with smaller decreases in baseline F2 (24 versus 42 µg/l at TDF initiation; P=0.01) and no considerable decrease in baseline F0-F1 (25 versus 31 µg/l at TDF initiation; P=0.9) groups ( Figure  1B ). By contrast, there was a slight but non-significant increase in median total bilirubin after 36 months of TDF among patients with baseline Fibrometer score F3-F4 (14 versus 12 µmol/l at TDF initiation; P=0.6) yet no change in baseline F2 (10 µmol/l at baseline and 36 months) and F0-F1 (7 versus 8 µmol/l at TDF initiation; P=0.8) groups ( Figure 1C ). In multivariable GEE analyses (Table 2) , HDV coinfection was a significant risk factor for increased Fibrometer score, with a mean score that was 0.086 (95% CI 0.027-0.145; P=0.005) higher in patients with Fibrometer F3-F4 during overall follow-up. It is noteworthy that HCV coinfection was not associated with an overall higher Fibrometer score. However, in subgroup analyses, HCV-negative patients with baseline F3-F4 score (n=34) had a larger decrease in Other risk factors for a significantly different fibrosis score included high serum HBV DNA (per log 10 IU/ml; P=0.02) and CD4 + T-cell count >350 cells/mm 3 (P=0.01) for patients with baseline F0-F2 and high serum HBV DNA viral load (P=0.02) for patients with baseline F3-F4. Additional models examining the confounding effect of NNRTI and PI classes, including other NRTIs, such as didanosine and stavudine, demonstrated no change in mean ∆.
Changes in biochemical
Fibrometer score during treatment The mean baseline Fibrometer score after adjustment for serum HBV viral load, treatment with lamivudine, age, CD4
Risk factors for modification of Fibrometer score during treatment
Improvement in liver fibrosis at the end of follow-up was observed in 22 (47.8%) and 14 (37.8%) patients Table 2 . Mean change from baseline in Fibrometer® scores among HIV-HBV-coinfected patients treated with TDF, stratified by baseline Fibrometer® scores of F0-F2 versus F3-F4
A multivariable generalized estimating equation regression model was fitted with an exchangeable working correlation to incorporate the within-patient correlation during follow-up. In this model, the following variables were mutually adjusted for in a multivariable analysis: duration of tenofovir disoproxil fumarate (TDF) therapy in 12-month intervals, serum HBV viral load, concomitant treatment with lamivudine, age divided at the median, CD4 + T-cell count divided at level indicated for treatment initiated, body mass index divided at the median, >4 glasses of alcohol consumption per day and presence of HCV and/or HDV infection. Covariables are interpreted as differences in the overall average of each risk factor and not as increases or decreases in score over follow-up. Adjusted ∆, adjusted change from baseline; CI, confidence interval. . Estimated duration of HBV infection also had a significant preventive effect on decreasing Fibrometer score with a 0.07 decrease in hazards/year of infection (95% CI 0.01-0.12). BMI was significantly associated with a decrease in fibrosis score; however, this association disappeared when BMI was used in the model as a reflection of overweight patients (>25 kg/m 2 ). Of note, no factors of fibrosis progression associated to antiviral or antiretroviral treatment were identified.
Histological changes in biopsy pairs during treatment
A total of 38 patients had at least two biopsies during the course of treatment with TDF (median time between baseline and follow-up biopsy 32.5 months [range 6.7-41.8]). When compared to patients without biopsies, patients with biopsies had very few differences with respect to several disease indicators. However, in the biopsy versus no biopsy groups, respectively, there was a higher percentage of males (97.4% versus 83.6%; P=0.03) and lower percentage of patients originating from regions of HBsAg prevalence >8% (7.9% versus 27.3%; P=0.03). In addition, patients with biopsy had a longer duration since first HBsAg-positive serology (9.6 versus 7.5 years; P=0.05) and a higher prevalence of HCV-positive serology (21.1% versus 10.0%; P=0.08) compared to patients without biopsies, indicating likely factors of increased fibrosis levels. Figure 3A and 3B summarizes the transitions of Metavir fibrosis and activity scores, respectively. Fibrosis scores at baseline were distributed as follows: F0-F1 n=8, F2 n=17 and F3-F4 n=13. A decrease in fibrosis score was observed in 9 (24%) patients (F3-F4 to F2 n=1, F3-F4 to F0-F1 n=1 and F2 to F0-F1 n=7) and 14 (37%) remained either with a score of F0-F1 (n=8) or F2 (n=6). Likewise, activity score decreased from A2-A3 to A0-A1 in 10 patients and increased from A0-A1 to A2-A3 in 2 patients; the remaining 26 patients had stable scores (A0-A1 n=20 and A2-A3 n=6).
A total of four patients had progressed from F2 to F3-F4 Metavir scores. One patient (F2 to F4 progression) had uncontrolled HBV DNA replication. The other three patients responded with undetectable levels (<60 IU/ml HBV DNA), but two patients had a hepatic flare (with ALT levels at 261 and 222 IU/ml), which required a liver biopsy as a diagnostic procedure for explaining their occurence.
Performance of Fibrometer in predicting histological scores and progression
Overall, fibrosis Metavir staging and Fibrometer equivalents were concordant (κ=0.45, intraclass correlation coefficient 0.63) with 63.6% of Fibrometer groups correctly classified. Progression of F2 to F3-F4 was poorly detected, as none of the four histologically confirmed cases of progression were identified as progressing based on the Fibrometer scores (κ=-0.08). However, Fibrometer might not be an accurate tool to detect fibrosis among these patients. Two had additional HCV infection, which could interfere with the Fibrometer score. Another patient had high HBV DNA replication (>20,000 IU/ml), despite normal biomarker levels (ALT 34 IU/ml and AST 33 IU/ml). By contrast, histologically confirmed decreases of scores corresponded well with biochemical decreases of F3-F4 to F2 (94.7% agreement, κ=0.48) and F2 to F0-F1 (79.0% agreement, κ=0.30).
Discussion
Using a novel non-invasive liver fibrosis score (Fibrometer), we analysed the effect of TDF on liver fibrosis during a 3-year prospective follow-up in a well-characterized HIV-HBV-coinfected population. We also established the risk factors associated with fibrosis evolution under treatment, as well as the prognostic factors influencing fibrogenesis.
Overall improvement in Fibrometer score was observed in 47.8% and 37.8% of patients classified as F3-F4 and F2 in Metavir staging, respectively. In patients with baseline F3-F4 Fibrometer stage, change had a triphasic shape, beginning with a steep decrease during the first 12 months, followed by a plateau of no change, then a slower decrease after 24 months in patients with advanced fibrosis and cirrhosis. In a cohort of 283 coinfected patients, an improvement of equal magnitude was noted with the FibroTest ® after lamivudine treatment initiation [21] , another biochemical surrogate score validated in HBV-monoinfected and HIV-HBV-coinfected patients [17, 24] . Although we could not confirm this n=103. ALP, alkaline phosphatase; ALT, alanine aminotransferase; anti-HBe, antibody against hepatitis B e antigen; BMI, body mass index; CI, confidence interval; GGT, γ-glutamyl transpeptidase; HBeAg, hepatitis B e antigen; NNRTI, non-nucleoside/nucleotide reverse transcriptase inhibitor; NRTI, nucleoside/ nucleotide reverse transcriptase inhibitor; PI, protease inhibitor; TDF, tenofovir disoproxil fumarate; ULN, upper limit of normal.
improvement by histological means in all patients, 38 of 148 patients included in the study underwent sequential liver biopsy and a majority exhibited either an improvement (24%) or stabilization (66%) of liver fibrosis. Only 4 (10.5%) patients experienced an increase in liver fibrosis. Information as to the histological effect of TDF was not available in the largest published trial conducted in HIV-HBV-coinfected patients [8] . In a smaller trial of 36 patients treated with lamivudine alone, TDF alone or lamivudine plus TDF, 15 had sequential liver biopsies: exacerbation of fibrosis was observed in 5 (33%) patients [9] . The difference when compared to our data might be partly explained by the longer duration of follow-up in our cohort, during which a clearer description of TDF efficacy could be assessed. In the trial conducted among HBV-monoinfected patients leading to the licensing of TDF in this population, 74% and 72% of HBeAg-positive and HBeAg-negative patients, respectively, had an improvement of fibrosis rated with the Knodell score after 48 weeks of treatment [13] .
In the 115 patients without cirrhosis at inclusion, incident cirrhosis was estimated at 4.5 per 100 personyears (10.4%) during follow-up. Two (2%) patients experienced liver decompensation and none died during follow-up. Natural history of liver fibrosis and compensated cirrhosis has been extensively studied in large cohorts of Asian HBV-monoinfected patients [25] . Reports on treatment-naive, HBV-monoinfected European patients mention a cumulative incidence of 10% and 29% of biopsy-proven fibrosis aggravation in HBeAg-positive and anti-HBe-antibody-positive patients, respectively, over a period of 4 years [26] . Data related to HIV-infected patients are more scant and are either cross-sectional [27] or retrospectively assessed among coinfected patients with mixed HIV-HBV or HIV-HBV-HCV patterns [28] . The first paper reported a prevalence of bridging fibrosis and cirrhosis evaluated with elastometry at 14% and 11%, respectively. The second paper showed a cumulative incidence of decompensated cirrhosis of 39.1%, but patients were also coinfected with mostly HCV. Of note, 27% of the study patients with incident cirrhosis and the two patients with hepatic failure were coinfected with HDV and/or HCV. Concurrent infection with HDV and/or HCV is a well known risk factor for cirrhosis in HIV-HBV-coinfected patients [29, 30] .
A significant decrease in hepatic enzymes was observed under treatment with TDF. Clinical trials evaluating the efficacy of TDF either in monoinfected or coinfected patients also reported a positive effect of TDF on transaminases [8, 13] . However, we report for the first time the influence of TDF on hyaluronic acid, a direct indicator related to the disintegration of the hepatic extracellular matrix [31] , whose decrease is particularly significant in the cirrhotic patients present in our study. This decrease might help explain the improvement in liver fibrosis that was particularly noticeable in patients with baseline F3-F4. Three groups of risk factors affecting the dynamics of liver fibrosis were identified in our study. The first group was linked to HIV disease: immunodeficiency (CD4 + T-cell count <350/mm 3 ) drove a higher overall level of fibrosis score and a reduced probability of fibrosis reversal while on treatment. Immunosuppression played a likely, additional role in fibrogenesis, through the persistent expression of proinflammatory cytokines, combined with the aberrant activity of stellate liver cells [32] . These findings support the need for earlier treatment in HIV-HBV-coinfected patients in whom a significant loss of CD4 + T-cells must be averted using an optimal antiretroviral regimen.
The second group refers to liver-related determinants that are common in HBV monoinfection. The HBV DNA level of replication was associated with a higher overall score in fibrosis in all baseline groups, whereas the duration of HBV infection was a prognostic factor of an absence in decreasing fibrosis score during follow-up. Studies pertaining to HBV-monoinfected patients have clearly established the role of HBV replication and duration of HBV infection in fibrogenesis and evolution towards cirrhosis and hepatocellular carcinoma [11, 12] . We confirm that patients with suboptimal virological control who have long-lasting HIV-HBV-coinfection are also at risk of progression towards bridging fibrosis and cirrhosis. Interestingly, patients classified as F0-F2 at baseline and concomitantly treated with lamivudine seemed slightly more at risk of an overall higher biochemical score of liver fibrosis. Of note, this molecule was part of HIV treatment and was not prescribed for HBV. YMDD mutations were, however, not a risk factor for transiting from a lower score to a higher score of fibrosis within the 3-year study period. A longer study period would probably be needed to better understand this finding.
The third group of risk factors is of host origin. Age was found to be independently associated with a decrease in the probability of fibrosis reversibility during TDF use. Age is a known risk factor for liver fibrosis in most studies of HBV-monoinfected patients, independent of any treatment. BMI has been recently found to increase the risk of hepatic damage in HBV infection [33] and was independent of causes such as non-alcoholic steatohepatitis, as seen in HIV-infected patients treated with antiretroviral treatment. In our study, a higher BMI seemed to be associated with fibrosis regression. However, this effect disappeared when we adjusted for overweight patients. Whether the association between BMI and liver fibrosis is a result of metabolic syndrome, as suggested in obese HBV-monoinfected patients [34] , remains to be demonstrated in the context of HIV. The high frequency of metabolic syndrome as a side-effect of antiretroviral use [35] might lead to an additive effect of BMI on fibrosis intensity. Unfortunately, there was little heterogeneity in BMI in our study population, therefore we could not fully investigate the effect that obesity has on liver fibrosis progression.
The limitations of our study must be acknowledged. First, biochemical scores are surrogate markers of liver fibrosis, none of which can provide an optimal compromise between sensitivity and specificity when compared to hepatic punch biopsy. Many biochemical scores have been developed in recent years, which are easier to use than liver biopsy, more acceptable to patients and repeatable over time; however, the aetiology of liver disease and the existence of comorbidities affect the performance of non-invasive markers and their cutoff values. The Fibrometer score has been identified within a panel of serum markers as having one of the best performance levels [36] . In our study, the agreement statistics between Metavir fibrosis and Fibrometer scores are similar to, if not higher than, those in a previous publication among HIV-HBVcoinfected patients by our research group (κ=0.28, 50% correctly classified) [17] . In our study sample, we chose not to use the FibroTest ® , another very popular biochemical score, because of the risk of false staging caused by the use of antiretrovirals, such as atazanavir (increase of bilirubin).
Second, interpretation of score changes might be difficult. The differences in overall scores among the significant adjusted risk factors might have little clinical effect and are dependant upon the level of fibrosis, as the change required to have a higher or lower Metavir fibrosis score is relatively large. For example, a patient with a Fibrometer score of 0.57, or Metavir F2 equivalent, would require an increase of 0.12 in order to achieve an equivalent of Metavir F3-F4 score. The largest overall average difference in adjusted Fibrometer score for the baseline F0-F2 group was HCV coinfection at 0.078. A 3-year follow-up might thus be too short to identify all relevant determinants involved in the dynamics of liver fibrosis. Numerous factors have, however, been identified in this cohort that are relevant to clinicians, and might help to better understand how to optimize fibrosis regression during TDF treatment.
Finally, the mean ∆ could be potentially influenced by outliers in the GEE models. As an alternative, we performed median GEE regression models using the same covariates and found similar conclusions. However, we chose to report the mean ∆ instead, because median GEE regression models can only be fitted using independent correlation structures that do not fully adapt the nature of repeated measurements [37] . Moreover, the influences of outliers should be minimal because the Fibrometer score is bound between 0 and 1 compared with, per se, other liver enzymes which range from 0 to infinity.
In conclusion, we provide, for the first time, insight regarding the dynamics of liver fibrosis under treatment with TDF in HIV-HBV-coinfected patients. Fibrosis regression followed a triphasic pattern with a rapid decrease during the first 12 months, a sustained period between 12 and 24 months, then a slower decrease after 24 months in patients with advanced fibrosis and cirrhosis. The identified determinants greatly influencing fibrosis evolution could be addressed by clinicians using simple interventions. These include earlier introduction of antiretrovirals for preventively limiting immunodeficiency, HCV and HDV treatment whenever possible, and optimization of HBV treatment, if appropriate, in patients with suboptimal virological control. Future longitudinal studies will need to address the sustainability of the direct antiviral and indirect antifibrotic effects described previously with TDF use, as well as determining its effect on the prevention of endstage liver disease in this population.
